# PDS Biotechnology Corp (PDSB) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_e373ae2203f0f87bce81 · retrieved 2026-08-11T16:09:37.441Z

## Overview
PDS Biotechnology Corporation is a pharmaceutical company developing immunotherapies and vaccines.

On July 30, 2026, PDS Biotechnology Corporation received a deficiency letter from Nasdaq notifying the company that its common stock closing bid price has fallen below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The company has been granted a 180-calendar-day compliance period, expiring January 26, 2027, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the company fails to regain compliance by the deadline, it may be eligible for a second 180-day compliance period if it meets other continued listing requirements. If compliance is not achieved, the company's common stock will become subject to delisting, though the company may appeal any delisting determination to a Nasdaq hearings panel.

## Terms
- Counterparty: Nasdaq Stock Market LLC · Price/share: $1

## Key dates
- Announced 2026-07-31 · Expiry 2027-01-26

## Timeline
- 2026-07-31 · 8-K (0001140361-26-030497): 8-K - PDS Biotechnology Corp — *PDS Biotechnology Corporation is a pharmaceutical company developing immunotherapies and vaccines.* On July 30, 2026, PDS Biotechnology Corporation received a deficiency letter from Nasdaq notifying the company that its common stock closing bid price has fallen below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(a)(2). The company has been granted a 180-calendar-day compliance period, expiring January 26, 2027, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the company fails to regain compliance by the deadline, it may be eligible for a second 180-day compliance period if it meets other continued listing requirements. If compliance is not achieved, the company's common stock will become subject to delisting, though the company may appeal any delisting determination to a Nasdaq hearings panel.
  https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-030497.txt

## Citations
- 0001140361-26-030497 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126030497